Global impact: How regulatory affairs is shaping development of cutting-edge pharma innovationWhen it comes to developing cutting-edge innovations, Astellas aims to be at the forefront. The pharma organisation prides Share XGlobal impact: How regulatory affairs is shaping development of cutting-edge pharma innovationhttps://pharmaphorum.com/views-and-analysis/global-impact-how-regulatory-affairs-is-shaping-development-of-cutting-edge-pharma-innovation/
NICE methods and process review aims to create fertile ground for innovationThe way NICE reviews new medicines is about to go through its biggest change in years – but Share XNICE methods and process review aims to create fertile ground for innovationhttps://pharmaphorum.com/views-and-analysis/nice-methods-and-process-review-aims-to-create-fertile-ground-for-innovation/
The Brexit deal; shot in the arm or kick in the teeth for the pharma sector?The UK Government and EU Commission trumpeted their Brexit trade deal, struck at the end of December, as Share XThe Brexit deal; shot in the arm or kick in the teeth for the pharma sector?https://pharmaphorum.com/market-access-2/the-brexit-deal-for-the-pharma-sector/
Life sciences must become cloud-first to seize the science of tomorrowIf the power of the life sciences industry to innovate and collaborate were ever in doubt, the speed Share XLife sciences must become cloud-first to seize the science of tomorrowhttps://pharmaphorum.com/views-analysis-digital/life-sciences-must-become-cloud-first-to-seize-the-science-of-tomorrow/
Pharma must adapt to embrace the opportunities of a new-look NHSFundamental changes to the way the NHS is structured and funded are afoot – and pharma needs to Share XPharma must adapt to embrace the opportunities of a new-look NHShttps://pharmaphorum.com/views-and-analysis/pharma-must-adapt-to-embrace-the-opportunities-of-a-new-look-nhs/
Lymphoma Action – championing the patient voice in cell therapyLymphoma Action is the only UK health charity dedicated to people affected by lymphoma. Chief Executive Ropinder Gill Share XLymphoma Action – championing the patient voice in cell therapyhttps://pharmaphorum.com/market-access-2/lymphoma-action-championing-the-patient-voice-in-cell-therapy/
2021 market access prospects for FranceIn the latest of a suite of features looking at the biggest markets in Europe, Leela Barham takes Share X2021 market access prospects for Francehttps://pharmaphorum.com/views-analysis-market-access/2021-market-access-prospects-for-france/
2021 market access prospects for Spain2021 will be the year when big market access changes – including the far wider use of health Share X2021 market access prospects for Spainhttps://pharmaphorum.com/views-analysis-market-access/2021-market-access-prospects-for-spain/
2021 market access prospects for GermanyThe market access landscape in Germany is particularly interesting in 2021, as a key component – AMNOG – Share X2021 market access prospects for Germanyhttps://pharmaphorum.com/views-analysis-market-access/2021-market-access-prospects-for-germany/
